
Opinion|Videos|February 28, 2024
Toxicity Profile of KRAS Targeted and Immunotherapy Combinations
Author(s)Hatim Husain, MD
Overview of side effects and management when combining these agents.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
3
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
4
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
5


















